About
Since moving to Australia from the UK with his family in 2023, Gareth has joined Graham Radford-Smith as a joint group leader for the Gut Health research team. He is also the Clinical Lead for IBD and Research for the Royal Brisbane and Women's Hospital, a Senior Lecturer at the University of Queensland and member of the ANZ IBD scientific committee.
Area of Interest
Gareth is interested in pharmacogenetics, spatial sequencing and AI prediction of IBD drug response. He is also interested in addressing healthcare inequality in remote and regional IBD care, as well as dietary interventions and their impacts on the gut ecosystem in IBD.
Professional Associations
ANZ IBD Scientific Committee, Royal Australasian College of Physicians (RACP), European Crohn's and Colitis Organisation (ECCO)
Funding
Takeda Grant (2024) - $50,000
Queensland Health Digital Transformation (2023) - $100,000
Publications
Little RD, McKenzie J, Srinivasan A et al. Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre andomized controlled trial. BMJ Open. 2024 Jul 20;14(7):e081787.
Natalie Yu, Danujan Sriranganathan, Gareth J Walker, Aleksejs Sazonovs, Helen Wilding, Christopher Roberts, Nicholas A Kennedy, Tariq Ahmad, Ray K Boyapati, Nik S Ding, Jonathan P Segal, Prevalence of NUDT15 Genetic Variants and Incidence of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis, Journal of Crohn's and Colitis, Volume 17, Issue 12, December 2023, Pages 1920–1930, https://doi.org/10.1093/ecco-jcc/jjad107
Chanchlani et.al, Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study. Aliment Pharmacol Ther. 2022 Oct;56(8):1250-1263. Epub 2022 Aug 29. PMID: 36039036; PMCID: PMC9804266. https://doi.org/10.1111/apt.17170